½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1444445

ÆÐÇ÷Áõ Áø´Ü : ¼¼°è ½ÃÀå Á¡À¯À² ºÐ¼®, ¾÷°è µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Global Sepsis Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÆÐÇ÷Áõ Áø´Ü ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 7¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 10¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£(2024-2029³â) Áß 6.58%ÀÇ CAGR·Î ¼ºÀåÇÕ´Ï´Ù.

¼¼°èÀÇ ÆÐÇ÷Áõ Áø´Ü-½ÃÀå

COVID-19 °¨¿° ȯÀÚÀÇ ÆÐÇ÷Áõ ¹ß»ý·ü Áõ°¡´Â Á¶»ç ´ë»ó ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)°¡ 2021³â ¹ßÇ¥ÇÑ '2020³â ±¹°¡ ¹× ÁÖ ÀÇ·á °ü·Ã °¨¿° ÁøÇà º¸°í¼­'¿¡ µû¸£¸é 2020³â ±Þ¼º±â º´¿øÀÇ Ç¥ÁØÈ­µÈ °¨¿°·üÀ» ºÐ¼®ÇÑ °á°ú ±Þ¼º±â º´¿øÀÇ °¨¿°·üÀÌ Å©°Ô Áõ°¡ÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. Áß½ÉÁ¤¸Æ°ü °ü·Ã Ç÷·ù°¨¿°, Ä«Å×ÅÍ °ü·Ã ¿ä·Î°¨¿°, ÀΰøÈ£Èí±â °ü·Ã »ç°Ç, ¸ÞƼ½Ç¸° ³»¼º Ȳ»öÆ÷µµ»ó±¸±Õ Ç÷ÁõÀÌ 2019³â¿¡ ºñÇØ Áõ°¡ÇÏ¿´½À´Ï´Ù. °¡Àå Å« Áõ°¡´Â 2020³â 4ºÐ±â¿¡ ¹ß»ýÇß½À´Ï´Ù. ¶ÇÇÑ PLOS°¡ 2019³â8¿ù¿¡ ¹ßÇ¥ ÇÑ ¿¬±¸¿¡ µû¸£¸é 2021³â8¿ù"¸é¿ª ´ë»ç ½Ã±×´Ïó´Â COVID-19 °¨¿°¿¡¼­ ÆÐÇ÷ÁõÀ¸·ÎÀÇ ÁøÇà À§ÇèÀ» ¿¹ÃøÇÑ´Ù"´Â ¿¬±¸¿¡ µû¸£¸é COVID-19 ȯÀÚ´Â ÆÐÇ÷Áõ ¹ßº´ À§ÇèÀÌ °¡Àå ³ô½À´Ï´Ù. µû¶ó¼­ ÀÌ´Â Á¶»ç ´ë»ó ½ÃÀå¿¡¼­ »õ·Î¿î Áø´ÜÀ» À§ÇÑ »õ·Î¿î ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÆÐÇ÷Áõ Áø´Ü ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ÆÐÇ÷Áõ ºÎ´ã Áõ°¡, º´¿ø³» °¨¿° ºÎ´ã Áõ°¡, Æó·Å ȯÀÚ ¼ö Áõ°¡, ÆÐÇ÷Áõ Ä¡·á °Ç¼ö Áõ°¡, ÆÐÇ÷Áõ¿¡ ´ëÇÑ ÀÚ±Ý Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. °ü·Ã ¿¬±¸ È°µ¿. º´¿ø³» °¨¿°(HAI)Àº ÀÔ¿ø ȯÀÚµé »çÀÌ¿¡¼­ °¡Àå ÈçÇÑ ÇÕº´ÁõÀÔ´Ï´Ù. ¿¹¸¦ µé¾î Áúº´ ÅëÁ¦ ¿¹¹æ ¼¾ÅÍ(CDC)°¡ 2021³â¿¡ ¹ßÇ¥ ÇÑ º¸°í¼­ "2020³â±¹°¡ ¹× ÁÖ ÀÇ·á °ü·Ã °¨¿° ÁøÇà º¸°í¼­"¿¡ µû¸£¸é Á߽ɼ±Àº ¾à 24%, 35%, 15% Áõ°¡Çß½À´Ï´Ù. 2019 -2020³â±îÁö ¹Ì±¹ÀÇ Ç÷·ù °¨¿°, ÀΰøÈ£Èí±â °ü·Ã »ç°Ç, ¸ÞƼ ½Ç¸° ³»¼º Ȳ»ö Æ÷µµ»ó ±¸±Õ(MRSA) ±ÕÇ÷Áõ. Ç÷·ù °¨¿° Áõ°¡´Â ÆÐÇ÷Áõ Áø´Ü Á¦Ç°ÀÇ Ã¤ÅÃÀ» Áõ°¡½Ãų °ÍÀÔ´Ï´Ù. ¶ÇÇÑ 2021³â 6¿ù, ¸®¹öÇ® ´ëÇÐÀÌ ÁÖµµÇÏ´Â °øµ¿ ¿¬±¸´Â ¸ð¼º ÆÐÇ÷ÁõÀ» Àû±ØÀûÀ¸·Î ¿¹¹æ, Ä¡·á ¹× Æò°¡Çϱâ À§ÇÑ »õ·Î¿î °³ÀÔÀ» À§ÇØ 300¸¸ ÆÄ¿îµå ÀÌ»óÀÇ ÀÚ±ÝÀ» Áö¿ø¹Þ¾Ò½À´Ï´Ù.

µû¶ó¼­ ÆÐÇ÷Áõ À¯º´·ü Áõ°¡¿Í ÆÐÇ÷Áõ Áø´ÜÀ» À§ÇÑ ¿¬±¸ È°µ¿¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡´Â ¿¹Ãø ±â°£ Áß Àüü ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÆÐÇ÷Áõ Áø´Ü ½ÃÀå µ¿Çâ

ºÐÀÚÁø´Ü ºÎ¹®Àº ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷Áö

ÆÐÇ÷ÁõÀº º´¿øÀÇ ¸¹Àº ȯÀڵ鿡°Ô ¿µÇâÀ» ¹ÌÄ¡¸ç, 6¹ø°·Î ¸¹Àº ÀÔ¿ø ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù. °¨¿°À» ÀÏÀ¸Å°´Â º´¿ø±ÕÀ» ½Å¼ÓÇÏ°í Á¤È®ÇÏ°Ô ÇÁ·ÎÆÄÀϸµÇÏ´Â °ÍÀº Çö´ë ÀÇ·á¿¡¼­ ¿©ÀüÈ÷ Å« µµÀü °úÁ¦ÀÔ´Ï´Ù. ¶ÇÇÑ ¿øÀÎ º´¿øüÀÇ ½Äº°Àº Ä¡·áÀÇ ÀÏȯÀ¸·Î ÀûÀýÇÑ Ç×»ýÁ¦ ¿ä¹ýÀ» ¼±ÅÃÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿ä±¸»çÇ×À¸·Î ÀÎÇØ ºÐÀÚÁø´Ü(MDx)Àº ÆÐÇ÷Áõ Áø´Ü¿¡ ÀÖÀ¸¸ç, ¸Å·ÂÀûÀÎ Á¢±Ù¹ýÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÐÀÚÁø´ÜÀº ½¬¿î ½ÇÇö °¡´É¼º°ú °ËÃâ ¹æ¹ýÀÇ Á¤È®¼ºÀ¸·Î ÀÎÇØ ¿©·¯ ´Ù±¹Àû ±â¾÷°ú ±â°üÀ» ¸Å·á½ÃÅ°°í ÀÖ½À´Ï´Ù. °¨¿°¼º ÁúȯÀÇ ½Å¼ÓÇÏ°í Á¤È®ÇÑ ÇÁ·ÎÆÄÀϸµÀ» À§ÇÑ Ç÷¾× ¹è¾ç ºÐ¼®Àº ºÐÀÚÁø´Ü ¹æ¹ýÀÇ È²±Ý Ç¥ÁØÀÔ´Ï´Ù. ±×·¯³ª ºÐÀÚÁø´ÜÀÇ ºñ¿ëÀº ¿©ÀüÈ÷ ±âÁ¸ ¹æ¹ý¿¡ ºñÇØ ¸Å¿ì ³ô±â ¶§¹®¿¡ ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇÏ°í ÀÖ½À´Ï´Ù. ÀϺΠ±â¾÷Àº ¼¼±Õ ¹× ¹ÙÀÌ·¯½º¼º º´¿ø±ÕÀÇ Á¶±â Áø´Ü°ú ȯÀÚ °ü¸®¸¦ °³¼±Çϱâ À§ÇØ ÇöÀå ºÐÀÚÁø´Ü¿¡ ÅõÀÚÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 10¿ù Immunexpress´Â À¯·´¿¡¼­ BiocartisÀÇ Idylla Ç÷§Æû¿¡¼­ ÆÐÇ÷Áõ¿¡ ´ëÇÑ 1½Ã°£ ºÐÀÚÁø´Ü Å×½ºÆ®ÀÎ Rapid SeptiCyte¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ´Â ÀÓ»óÀÇÀÇ ÆÐÇ÷Áõ Áø´ÜÀ» Áö¿øÇϱâ À§ÇØ ¸é¿ª ¹ÝÀÀ¿¡ ±â¹ÝÇÑ ÃÖÃÊÀÇ ¿ÏÀü ÅëÇÕÇü ½Å¼Ó °Ë»ç Áß ÇϳªÀÔ´Ï´Ù.

¿¬±¸ÁøÀº ¶ÇÇÑ COVID-19¿Í ÆÐÇ÷ÁõÀ» °¨ÁöÇÏ°í ±¸º°ÇÒ ¼ö ÀÖ´Â ºÐÀÚÁø´Ü¹ýÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇÏ°í ÀÖ½À´Ï´Ù. 2020³â 11¿ù, ±×¸®½º ÆÐÇ÷Áõ ¿¬±¸¼Ò¿Í Sanmina CorporationÀÇ ÀϺΰ¡ ¿¬±¸ ÀÚ±ÝÀ» Áö¿øÇÏ¿© ÆÐÇ÷Áõ°ú ÁßÁõ COVID-19ÀÇ Á¶±â Áø´ÜÀ» À§ÇÑ »õ·Î¿î ±¤ÇÐ ¹ÙÀÌ¿À¼¾¼­¸¦ °³¹ßÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀºÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì ½ÃÀåÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

ºÏ¹Ì´Â ÆÐÇ÷Áõ Áø´Ü ½ÃÀå¿¡¼­ Å« ºñÁßÀ» Â÷ÁöÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç, ¿¹Ãø ±â°£ Áß Å« º¯µ¿ ¾øÀÌ ºñ½ÁÇÑ Ãß¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)¿¡ µû¸£¸é 2021³â 8¿ù ±âÁØ ¹Ì±¹ ¼ºÀÎ ¾à 170¸¸ ¸íÀÌ ÆÐÇ÷Áõ¿¡ °É·ÈÀ¸¸ç, ¾à 27¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ÆÐÇ÷ÁõÀ¸·Î »ç¸ÁÇß½À´Ï´Ù. ¶ÇÇÑ º´¿ø¿¡¼­ »ç¸ÁÇϴ ȯÀÚ 3¸í Áß 1¸íÀº ÆÐÇ÷ÁõÀ¸·Î »ç¸ÁÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. µû¶ó¼­ ¹Ì±¹³» ÀÌ Áúº´ÀÇ ³ôÀº ¹ßº´·üÀº Áø´ÜÀ» Áõ°¡½ÃÅ°°í ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

¶ÇÇÑ ÆÐÇ÷Áõ Áø´ÜÀ» À§ÇÑ ¿¬±¸°³¹ß ºÐ¾ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡µµ ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 4¿ù Cytovale Inc.´Â COVID-19¸¦ Æ÷ÇÔÇÑ ÀáÀçÀû È£Èí±â °¨¿° ȯÀÚÀÇ ÆÐÇ÷Áõ Áø´ÜÀ» À§ÇØ »ý¹° ÀÇÇР÷´Ü ¿¬±¸ ¹× °³¹ß °³¹ß±¹(BARDA)°ú COVID-19¸¦ È®´ëÇß½À´Ï´Ù. ÀÌ ¿¬±¸¿¡´Â 590¸¸ ´Þ·¯ÀÇ ºñ¿ëÀÌ ¼Ò¿äµÉ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ±× Áß ¾à 3.83 ´Þ·¯´Â »ý¹° ÀÇÇР÷´Ü ¿¬±¸°³¹ß °³¹ß±¹(BARDA)¿¡¼­ ±âºÎÇÏ¿© ½ÃÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù.

µû¶ó¼­ ÆÐÇ÷Áõ À¯º´·ü Áõ°¡¿Í ÆÐÇ÷Áõ Áø´Ü ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ¹Ì±¹ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÆÐÇ÷Áõ Áø´Ü »ê¾÷ °³¿ä

ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀº ¼Ò¼öÀÇ ÁÖ¿ä ±â¾÷ÀÌ Á¸ÀçÇÏ¿© ¾î´À Á¤µµ ÅëÇյǾî ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ÀÌ Ãâ½ÃÇÑ Á¦Ç°°ú ÁÖ¿ä ±â¾÷ÀÇ ÆÐÇ÷Áõ Áø´Ü¿¡ ´ëÇÑ ¿¬±¸ ±¸»óÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ÁøÃâ±â¾÷À¸·Î´Â Abbott, Becton, Dickinson and Company, bioMerieux SA, Bruker Corporation, F. Hoffmann-LA Roche Ltd, Immunexpress Inc. µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½ÄÀÇ ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ÀÇ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ÃËÁø¿äÀÎ
    • ÆÐÇ÷ÁõÀÇ ºÎ´ã Áõ´ë
    • ¿ø³»°¨¿°ÀÇ Áõ°¡
    • ÆÐÇ÷Áõ ¼ö¼ú °Ç¼öÀÇ Áõ°¡¿Í ÆÐÇ÷Áõ °ü·Ã Á¶»ç È°µ¿¿¡ ´ëÇÑ ÀÚ±Ý Á¦°øÀÇ Áõ°¡
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ÀÚµ¿ Áø´Ü ±â±âÀÇ °íºñ¿ë
    • ÆÐÇ÷Áõ¿¡ ´ëÇÑ È®¸³µÈ »óȯ Á¤Ã¥ÀÇ °á¿©
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀïÀÇ °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • ±â¼úº°
    • ºÐÀÚÁø´ÜÇÐ
    • ¹Ì»ý¹°ÇÐ
    • ¸é¿ªÃøÁ¤¹ý
    • ±âŸ ±â¼ú
  • Á¦Ç°º°
    • ±â±â
    • ¾î¼¼ÀÌ¿Í ½Ã¾à
    • ±âŸ Á¦Ç°
  • Áø´Ü ¹æ¹ýº°
    • ±âÁ¸ Áø´Ü
    • ÀÚµ¿ Áø´Ü
  • º´¿øüº°
    • ¼¼±Õ¼º ÆÐÇ÷Áõ
    • Áø±Õ¼º ÆÐÇ÷Áõ
    • ±âŸ º´¿øü
  • Áö¿ªº°
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîƼ³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Abbott Laboratories Inc.
    • Axis-Shield Diagnostics Ltd
    • Becton, Dickinson, and Company
    • BioMerieux SA
    • Bruker Corporation
    • Cube Dx GmbH
    • Danaher Corporation
    • EKF Diagnostics
    • F. Hoffmann-LA Roche Ltd
    • Immunexpress Inc.
    • Diasorin
    • Response Biomedical Corp.
    • Sysmex Corporation
    • T2 Biosystems Inc.
    • Thermo Fisher Scientific

Á¦7Àå ½ÃÀå ±âȸ¿Í ÇâÈÄ µ¿Çâ

KSA 24.03.18

The Global Sepsis Diagnostics Market size is estimated at USD 0.74 billion in 2024, and is expected to reach USD 1.02 billion by 2029, growing at a CAGR of 6.58% during the forecast period (2024-2029).

Global Sepsis Diagnostics - Market

Increasing incidences of sepsis in COVID-19 patients is anticipated to have a positive impact on the market studied. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', the analysis of the 2020 acute care hospitals standardized infection ratios found significant increases in central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated events, and methicillin-resistant Staphylococcus aureus bacteremia compared to 2019. The largest increases occurred during quarter 4 of 2020. Furthermore, according to a study published by PLOS in August 2021, 'Immunometabolic signatures predict the risk of progression to sepsis in COVID-19,' COVID-19 patients are at the highest risk of developing sepsis. Hence, this is expected to create new opportunities for novel diagnosis in the market studied.

The major factors for the growth of the sepsis diagnostics market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', about 24%, 35%, and 15% increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia between 2019 and 2020 in the United States. The rising bloodstream infections will lead to increased adoption of sepsis diagnostic products. Additionally, in June 2021, the collaboration led by the University of Liverpool has received more than GBP 3 million in funding for a new intervention that will actively prevent, treat and evaluate maternal sepsis.

Thus, the rise in the prevalence of sepsis and increase in funding for research activities for sepsis diagnosis are expected to drive the overall growth of the sepsis diagnosis market over the forecast period.

Sepsis Diagnosis Market Trends

The Molecular Diagnostics Segment Has a Significant Share in the Market

Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics.

Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis' Idylla platform. This is one of the first rapid, fully-integrated, and immune response-based tests to aid clinicians with a sepsis diagnosis.

Furthermore, researchers are attempting to develop a molecular diagnostic that can detect the COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of this segment.

North America is Expected to Hold a Large Share of the Market

North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the Centers for Disease Control and Prevention, in August 2021, approximately 1.7 million adults in America develop sepsis, and nearly 270,000 Americans die due to sepsis. It was also found that 1 in 3 patients who die in a hospital has sepsis. Thus, the high incidence rate of the disease in the country will boost its diagnosis, thus, boosting the market.

Moreover, rising investments in the fields of research and development for the diagnosis of sepsis will also boost the market. For instance, in April 2020, Cytovale Inc. expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for diagnosing sepsis in patients with potential respiratory infections, including COVID-19. The research is estimated to stand at the cost of USD 5.9 million, with approximately USD 3.83 contributed by the Biomedical Advanced Research and Development Authority (BARDA), thus, driving the market.

Therefore, the rising prevalence of sepsis and increasing investments in the research and development of sepsis diagnosis may augment the growth of the market in the United States.

Sepsis Diagnosis Industry Overview

The sepsis diagnostics market is moderately consolidated owing to the presence of a few key players. The market is expected to drive due to the products launched by the key players in the market and the rise in research initiatives on sepsis diagnostics by the key players. Some of the market players are Abbott, Becton, Dickinson, and Company, bioMerieux SA, Bruker Corporation, F. Hoffmann-LA Roche Ltd, and Immunexpress Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Sepsis
    • 4.2.2 Growing Incidence of Hospital-acquired Infections
    • 4.2.3 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-related Research Activities
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Automated Diagnostic Instruments
    • 4.3.2 Lack of Well-established Reimbursement Policies for Sepsis
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technology
    • 5.1.1 Molecular Diagnostics
    • 5.1.2 Microbiology
    • 5.1.3 Immunoassay
    • 5.1.4 Other Technologies
  • 5.2 By Product
    • 5.2.1 Instruments
    • 5.2.2 Assays and Reagents
    • 5.2.3 Other Products
  • 5.3 By Diagnostic Method
    • 5.3.1 Conventional Diagnostics
    • 5.3.2 Automated Diagnostics
  • 5.4 By Pathogen
    • 5.4.1 Bacterial Sepsis
    • 5.4.2 Fungal Sepsis
    • 5.4.3 Other Pathogens
  • 5.5 By Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories Inc.
    • 6.1.2 Axis-Shield Diagnostics Ltd
    • 6.1.3 Becton, Dickinson, and Company
    • 6.1.4 BioMerieux SA
    • 6.1.5 Bruker Corporation
    • 6.1.6 Cube Dx GmbH
    • 6.1.7 Danaher Corporation
    • 6.1.8 EKF Diagnostics
    • 6.1.9 F. Hoffmann-LA Roche Ltd
    • 6.1.10 Immunexpress Inc.
    • 6.1.11 Diasorin
    • 6.1.12 Response Biomedical Corp.
    • 6.1.13 Sysmex Corporation
    • 6.1.14 T2 Biosystems Inc.
    • 6.1.15 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦